STAT

Expanding addiction treatment, embracing the bully pulpit: Jerome Adams on his first year as surgeon general

STAT caught up with Surgeon General Jerome Adams as he marks his first year on the job to learn about his plans for year two and hear his thoughts about…
Surgeon General Jerome Adams at the White House.

Earlier this month, Dr. Jerome Adams marked one year as surgeon general — a position nicknamed “America’s doctor.” In that time, he’s worked with the Trump administration as it declared the opioid epidemic a public health emergencytraveled to 26 states, Puerto Rico, and the U.S. Virgin Islands; and issued a rare advisory that has led to more Americans carrying naloxone.

On Thursday, Adams also released a report containing the latest opioid data and recommendations for what people can do to stem the addiction crisis. The initiative includes a digital postcard that Adams likened to the pamphlet about AIDS former Surgeon General C. Everett Koop mailed to every household in 1988. The postcard highlights properly storing and disposing opioid medications, other options for pain treatment beyond opioids, and treatments that exist for opioid addiction.

STAT caught up with Adams this week to see how the first year went, learn about his plans for year two, and hear his thoughts about some of the most pressing public health debates today, including safe injection sites, also known as supervised injection facilities, which a number of cities are hoping to open. Adams also updated STAT about his wife, Lacey, who is undergoing treatment for metastatic melanoma, and his brother, Phillip, who for years has struggled with addiction and is in a Maryland prison.

Adams, a trained anesthesiologist, previously served as Indiana state health commissioner, a post

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

Related Books & Audiobooks